Drug Description
100 mg: Each film-coated tablet contains 100 mg rufinamide.Excipient: 20 mg lactose monohydrate/film coated tablet. 200 mg: Each film-coated tablet contains 200 mg rufinamide.Excipient: 40 mg lactose monohydrate/film coated tablet. 400 mg: Each film-coated tablet contains 400 mg rufinamide.Excipient: 80 mg lactose monohydrate/film coated tablet.
Presentation
Film-coated tablets.100 mg: Pink, 'ovaloid', slightly convex, scored on both sides, embossed '?261' on one side and blank on the other side.200 mg: Pink, 'ovaloid', slightly convex, scored on both sides, embossed '?262' on one side and blank on the other side.400 mg: Pink, 'ovaloid', slightly convex, scored on both sides, embossed '?263' on one side and blank on the other side.The tablets can be divided into equal halves.
Indications
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with LennoxGastaut syndrome in patients 4 years and older.
Adult Dosage
Treatment with Inovelon should be initiated by a physician specialised in paediatrics or neurology with experience in the treatment of epilepsy.
Inovelon is for oral use. It should be taken twice daily with water in the morning and in the evening, in two equally divided doses. As a food effect was observed, it will preferable to administer Inovelon with food. If the patient has difficulty with swallowing, tablets can be crushed and administered in half a glass of water.
Use in adults and children four years of age or older of 30 kg or over
